Patients with non-metastatic castrate-resistant prostate cancer (nmCRPC) face rising PSA despite ongoing androgen deprivation therapy (ADT) and no detectable metastases by conventional imaging. ¹ Novel treatments such as androgen receptor inhibitors have shown significant improvement to nmCRPC patients on top of androgen deprivation therapy (ADT).

Join us in this webinar featuring A/Prof. Azad ARUN and Prof. Karim FIZAZI, as we explore the landscape of nmCRPC, benefits of early treatment, and latest clinical data for nmCRPC disease management. Moderated by Dr. Ravindran KANESVARAN (Dr. Kanesvaran is a Senior Consultant in the Division of Medical Oncology at National Cancer Centre Singapore).

We welcome you to send us your questions beforehand so that we can ensure that they get answered during this talk show.

This webinar will cover:
- nmCRPC : A Fact or Fiction

- nmCRPC : Impact of Treatment on Survival

¹ Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine 2019;380:1235-46.

If you are unable to access the registration link, please send us the following details via email to sso@singaporeoncology.org.sg and we will send you the webinar link.

First Name* :

Last Name :*

Organisation* :

Email* :

Country* :

MCR Number :